We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Electrochemical Sensor Detects Bird Flu

By HospiMedica staff writers
Posted on 12 Jun 2006
A new sensor of biologic substances has demonstrated a capability for the instantaneous detection of the H5N1 strain of avian influenza. More...


The real-time SmartSense detector, manufactured by BioWarn (Montgomery Village, MD, USA), uses a microchip to capture the electronic signature produced when the surface of the H5N1 strain contacts the sensor. Like a lock and key, this SmartSense detector is triggered only by the H5N1 target. The detector then automatically wirelessly transmits the identifying information to users.

In addition to the H5N1 strain of avian flu, potential targets include HIV; tuberculosis; hospital-acquired infectious agents such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), or E coli; bio-terrorism agents such as anthrax or smallpox; and any biomolecule that can bind to a SmartSense detector.

Using extremely small samples, SmartSense devices detect a target's presence based on electrochemical signatures that are immediately detectable and that are unique to each target. Detection is direct, positive, and binary, based on unique interaction signatures at the molecular level. Binding of the target molecule to the detector creates a real-time readout.

"Today, there are more unseen and dangerous threats to our health than ever before. Detecting avian flu using BioWarn's SmartSense system is a major breakthrough,” said Dr. James P. Wade, Jr., chairman of the board and CEO of BioWarn. "Using SmartSense, an outbreak of human avian flu can be detected and isolated in its early stages so that prevention, vaccines, and treatment can immediately be administered.”



Related Links:
BioWarn

Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.